{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:41:09Z","timestamp":1791258069417,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"40","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502235"],"award-info":[{"award-number":["81502235"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fructose-1,6-bisphosphatase (FBP1) is a rate-limiting enzyme in gluconeogenesis and an important tumor suppressor in human malignancies. Here, we aimed to investigate the expression profile of FBP1 in ovarian cancer, the molecular mechanisms that regulate FBP1 expression and to examine how the FBP1 regulatory axis contributes to tumorigenesis and progression in ovarian cancer. We showed that FBP1 expression was significantly decreased in ovarian cancer tissues compared with normal ovarian tissues, and low-FBP1 expression predicted poor prognosis in patients with ovarian cancer. The enhanced expression of FBP1 in ovarian cancer cell lines suppressed proliferation and 2-D\/3-D invasion, reduced aerobic glycolysis, and sensitized cancer cells to cisplatin-induced apoptosis. Moreover, DNA methylation and C-MYC binding at the promoter inhibited FBP1 expression. Furthermore, through physical interactions with signal transducer and activator of transcription 3 (STAT3), FBP1 suppressed nuclear translocation of STAT3 and exerted its non-metabolic enzymatic activity to induce the dysfunction of STAT3. Thus, our study suggests that FBP1 may be a valuable prognostic predictor for ovarian cancer. C-MYC-dependent downregulation of FBP1 acted as a tumor suppressor via modulating STAT3, and the C-MYC\/FBP1\/STAT3 axis could be a therapeutic target.<\/jats:p>","DOI":"10.1038\/s41388-021-01957-5","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T10:12:32Z","timestamp":1628244752000},"page":"5938-5949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC\/STAT3 signaling axis in ovarian cancer"],"prefix":"10.1038","volume":"40","author":[{"given":"Haoran","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-3736","authenticated-orcid":false,"given":"Yongdong","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-5112","authenticated-orcid":false,"given":"Xi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-6608","authenticated-orcid":false,"given":"Midie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-5887","authenticated-orcid":false,"given":"Ziliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"1957_CR1","first-page":"7","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA: Cancer J Clin"},{"key":"1957_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/clpt.2012.237","volume":"93","author":"D Gonzalez de Castro","year":"2013","unstructured":"Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther. 2013;93:252\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1957_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O. On the origin of cancer cells. Science. 1956;123:309\u201314.","journal-title":"Science"},{"key":"1957_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"1957_CR5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GIM.0b013e31818b0d9b","volume":"10","author":"RJ DeBerardinis","year":"2008","unstructured":"DeBerardinis RJ. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med. 2008;10:767\u201377.","journal-title":"Genet Med"},{"key":"1957_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0969-2126(98)00021-5","volume":"6","author":"MS Jurica","year":"1998","unstructured":"Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T, Stoddard BL. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure. 1998;6:195\u2013210.","journal-title":"Structure"},{"key":"1957_CR7","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1111\/j.1742-4658.2006.05214.x","volume":"273","author":"A Marin-Hernandez","year":"2006","unstructured":"Marin-Hernandez A, Rodriguez-Enriquez S, Vital-Gonzalez PA, Flores-Rodriguez FL, Macias-Silva M, Sosa-Garrocho M, et al. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J. 2006;273:1975\u201388.","journal-title":"FEBS J"},{"key":"1957_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3109\/07357907.2015.1020385","volume":"33","author":"H Sheng","year":"2015","unstructured":"Sheng H, Ying L, Zheng L, Zhang D, Zhu C, Wu J, et al. Down expression of FBP1 is a negative prognostic factor for non-small-cell lung cancer. Cancer Investig. 2015;33:197\u2013204.","journal-title":"Cancer Investig"},{"key":"1957_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11010-015-2595-8","volume":"411","author":"J Zhang","year":"2016","unstructured":"Zhang J, Wang J, Xing H, Li Q, Zhao Q, Li J. Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells. Mol Cell Biochem. 2016;411:331\u201340.","journal-title":"Mol Cell Biochem"},{"key":"1957_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ccr.2013.01.022","volume":"23","author":"C Dong","year":"2013","unstructured":"Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013;23:316\u201331.","journal-title":"Cancer Cell"},{"key":"1957_CR11","doi-asserted-by":"crossref","first-page":"101042831770877","DOI":"10.1177\/1010428317708779","volume":"39","author":"Y Liu","year":"2017","unstructured":"Liu Y, Jiang Y, Wang N, Jin Q, Ji F, Zhong C, et al. Invalidation of mitophagy by FBP1-mediated repression promotes apoptosis in breast cancer. Tumour Biol. 2017;39:1010428317708779.","journal-title":"Tumour Biol"},{"key":"1957_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4149\/neo_2017_407","volume":"64","author":"L Shi","year":"2017","unstructured":"Shi L, He C, Li Z, Wang Z, Zhang Q. FBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1alpha. Neoplasma. 2017;64:535\u201342.","journal-title":"Neoplasma"},{"key":"1957_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature13557","volume":"513","author":"B Li","year":"2014","unstructured":"Li B, Qiu B, Lee DS, Walton ZE, Ochocki JD, Mathew LK, et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature. 2014;513:251\u20135.","journal-title":"Nature"},{"key":"1957_CR14","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1158\/0008-5472.CAN-16-3143","volume":"77","author":"X Jin","year":"2017","unstructured":"Jin X, Pan Y, Wang L, Ma T, Zhang L, Tang AH, et al. Fructose-1,6-bisphosphatase Inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1-MAPK interaction. Cancer Res. 2017;77:4328\u201341.","journal-title":"Cancer Res"},{"key":"1957_CR15","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.bbrc.2008.10.045","volume":"377","author":"M Bigl","year":"2008","unstructured":"Bigl M, Jandrig B, Horn LC, Eschrich K. Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer. Biochem Biophys Res Commun. 2008;377:720\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"1957_CR16","doi-asserted-by":"publisher","first-page":"e25564","DOI":"10.1371\/journal.pone.0025564","volume":"6","author":"M Chen","year":"2011","unstructured":"Chen M, Zhang J, Li N, Qian Z, Zhu M, Li Q, et al. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS ONE. 2011;6:e25564.","journal-title":"PLoS ONE"},{"key":"1957_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/onc.2009.332","volume":"29","author":"X Liu","year":"2010","unstructured":"Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS, et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene. 2010;29:442\u201350.","journal-title":"Oncogene"},{"key":"1957_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1530\/ERC-11-0329","volume":"19","author":"B Gyorffy","year":"2012","unstructured":"Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19:197\u2013208.","journal-title":"Endocr Relat Cancer"},{"key":"1957_CR19","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1080\/15384101.2019.1648956","volume":"18","author":"YP Zhang","year":"2019","unstructured":"Zhang YP, Liu KL, Yang Z, Lu BS, Qi JC, Han ZW, et al. The involvement of FBP1 in prostate cancer cell epithelial mesenchymal transition, invasion and metastasis by regulating the MAPK signaling pathway. Cell Cycle. 2019;18:2432\u201346.","journal-title":"Cell Cycle"},{"key":"1957_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"1957_CR21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.cmet.2015.09.025","volume":"22","author":"AJ Bott","year":"2015","unstructured":"Bott AJ, Peng IC, Fan Y, Faubert B, Zhao L, Li J, et al. Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metab. 2015;22:1068\u201377.","journal-title":"Cell Metab"},{"key":"1957_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/jcp.24698","volume":"230","author":"P Garrido","year":"2015","unstructured":"Garrido P, Osorio FG, Moran J, Cabello E, Alonso A, Freije JM, et al. Loss of GLUT4 induces metabolic reprogramming and impairs viability of breast cancer cells. J Cell Physiol. 2015;230:191\u20138.","journal-title":"J Cell Physiol"},{"key":"1957_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-11-41","volume":"11","author":"MA Soh","year":"2011","unstructured":"Soh MA, Garrett SH, Somji S, Dunlevy JR, Zhou XD, Sens MA, et al. Arsenic, cadmium and neuron specific enolase (ENO2, gamma-enolase) expression in breast cancer. Cancer Cell Int. 2011;11:41.","journal-title":"Cancer Cell Int"},{"key":"1957_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.7150\/thno.38137","volume":"10","author":"B Wang","year":"2020","unstructured":"Wang B, Zhou Y, Zhang J, Jin X, Wu H, Huang H. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Theranostics. 2020;10:1033\u201345.","journal-title":"Theranostics"},{"key":"1957_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/1947601910377495","volume":"1","author":"MD Delgado","year":"2010","unstructured":"Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. Genes Cancer. 2010;1:605\u201316.","journal-title":"Genes Cancer"},{"key":"1957_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV. MYC on the path to cancer. Cell. 2012;149:22\u201335.","journal-title":"Cell"},{"key":"1957_CR27","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.biopha.2016.10.050","volume":"84","author":"KC Li","year":"2016","unstructured":"Li KC, Ying MZ, Feng D, Du JE, Chen SY, Dan B, et al. Fructose-1,6-bisphosphatase is a novel regulator of Wnt\/beta-Catenin pathway in breast cancer. Biomed Pharmacother. 2016;84:1144\u20139.","journal-title":"Biomed Pharmacother"},{"key":"1957_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11010-020-03958-6","volume":"476","author":"J Qiu","year":"2021","unstructured":"Qiu J, Yang B. MAGE-C2\/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer (Jul, 10.1007\/s11010-020-03814-7, 2020). Mol Cell Biochem. 2021;476:11\u201311.","journal-title":"Mol Cell Biochem"},{"key":"1957_CR29","doi-asserted-by":"publisher","first-page":"224.","DOI":"10.1186\/s13046-018-0888-y","volume":"37","author":"B Wang","year":"2018","unstructured":"Wang B, Fan P, Zhao JY, Wu HY, Jin X, Wu HS. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma. J Exp Clin Canc Res. 2018;37:224.","journal-title":"J Exp Clin Canc Res"},{"key":"1957_CR30","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1007\/s00018-008-8224-x","volume":"65","author":"SJ Yeung","year":"2008","unstructured":"Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci. 2008;65:3981\u201399.","journal-title":"Cell Mol Life Sci"},{"key":"1957_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2015.08.003","volume":"43","author":"AL Hsieh","year":"2015","unstructured":"Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015;43:11\u201321.","journal-title":"Semin Cell Dev Biol"},{"key":"1957_CR32","doi-asserted-by":"publisher","first-page":"4136.","DOI":"10.3390\/ijms20174136","volume":"20","author":"SH Chen","year":"2019","unstructured":"Chen SH, Chang JY. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int J Mol Sci. 2019;20:4136.","journal-title":"Int J Mol Sci"},{"key":"1957_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ygyno.2016.06.005","volume":"142","author":"M Hijaz","year":"2016","unstructured":"Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, et al. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. Gynecol Oncol. 2016;142:323\u201331.","journal-title":"Gynecol Oncol"},{"key":"1957_CR34","first-page":"3086","volume":"10","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Zhu J, Zhang HY, Liu YM, Sun H. Metformin inhibits ovarian cancer growth and migration in vitro and in vivo by enhancing cisplatin cytotoxicity. Am J Transl Res. 2018;10:3086\u201398.","journal-title":"Am J Transl Res"},{"key":"1957_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2016.01.009","volume":"373","author":"Z Ai","year":"2016","unstructured":"Ai Z, Lu Y, Qiu S, Fan Z. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett. 2016;373:36\u201344.","journal-title":"Cancer Lett"},{"key":"1957_CR36","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1182\/blood-2008-05-157842","volume":"113","author":"E Hulleman","year":"2009","unstructured":"Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJC, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009;113:2014\u201321.","journal-title":"Blood"},{"key":"1957_CR37","doi-asserted-by":"publisher","first-page":"371 e371","DOI":"10.1016\/j.ajog.2009.10.883","volume":"202","author":"P Loar","year":"2010","unstructured":"Loar P, Wahl H, Kshirsagar M, Gossner G, Griffith K, Liu JR. Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol. 2010;202:371 e371\u2013378.","journal-title":"Am J Obstet Gynecol"},{"key":"1957_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00432-010-0860-5","volume":"137","author":"WH Guo","year":"2011","unstructured":"Guo WH, Zhang Y, Chen T, Wang YS, Xue JX, Zhang YG, et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin. 2011;137:65\u201372.","journal-title":"J Cancer Res Clin"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01957-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T08:36:26Z","timestamp":1633595786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01957-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":38,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2021,10,7]]}},"alternative-id":["1957"],"URL":"https:\/\/doi.org\/10.1038\/s41388-021-01957-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}